Anbio Biotechnology (NNNN) vs OraSure Technologies (OSUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OraSure Technologies (OSUR) has outperformed Anbio Biotechnology (NNNN) over the past year, gaining 17.1% versus a loss of 85.1%. OraSure Technologies is the larger company by market cap ($261.7 million vs $202.8 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NNNN | OSUR |
|---|---|---|
| Share price | $4.62 | $3.80 |
| Market cap | $202.78M | $261.74M |
| 1-day change | -5.71% | +1.74% |
| YTD return | -84.64% | +56.82% |
| 1-year return | -85.09% | +17.13% |
| 5-year return | — | -63.89% |
| P/E ratio (TTM) | 30.80 | — |
| EPS (TTM) | $0.15 | $-0.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $44.73 | $4.58 |
| 52-week low | $4.55 | $2.08 |
| Distance from 52-week high | -89.67% | -17.14% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +5.40% |
| Average volume | 146.84K | 484.72K |
| Shares outstanding | 43.89M | 68.97M |
| Employees | 27 | 500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OSUR has outperformed NNNN by 102.2 percentage points over the past year.
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
About OraSure Technologies
OSUR stock →OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
Health Care · Medical/Dental Instruments · 500 employees
NNNN vs OSUR FAQ
Which is bigger, Anbio Biotechnology or OraSure Technologies?
OraSure Technologies (OSUR) is larger, with a market capitalization of $261.74M compared with $202.78M for Anbio Biotechnology (NNNN).
Which stock has performed better over the past year, NNNN or OSUR?
OSUR returned +17.13% over the past 12 months, compared with -85.09% for NNNN (price return, excluding dividends). Past performance does not predict future results.
Are Anbio Biotechnology and OraSure Technologies in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for Anbio Biotechnology and Medical/Dental Instruments for OraSure Technologies.